Standout Papers

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderat... 2021 2026 2022 2024199
  1. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial (2021)
    Sarah Diver, Latifa Khalfaoui et al. The Lancet Respiratory Medicine

Immediate Impact

1 from Science/Nature 54 standout
Sub-graph 1 of 23

Citing Papers

Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps
2025 Standout
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma
2024 Standout
2 intermediate papers

Works of James Johnston being referenced

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial
2021 Standout

Author Peers

Author Last Decade Papers Cites
James Johnston 182 292 147 33 678
Alicja Grzanka 48 172 41 48 583
Antoine Azar 148 199 119 34 619
Catherine R. Weiler 93 136 197 51 785
Peter Olsson 64 432 181 34 840
R. M. Mulligan 112 225 140 28 582
Robert A. Mickel 213 181 235 30 774
NW Savage 49 156 152 40 848
Masahiro Ogawa 105 166 59 31 600
Rolf Haye 90 247 187 46 834
Soon Jae Hwang 85 124 165 41 600

All Works

Loading papers...

Rankless by CCL
2026